GT Biopharma Deploys AI to Accelerate Pipeline Discovery, Eyes Multiple Pre-IND Candidates in 2027
GTBP•GT Biopharma has integrated AI-driven sequence and structural analyses to identify de novo tumor-targeting engagers and multi-domain proteins, accelerating discovery while cutting development costs and timelines. The company expects multiple new candidates to enter pre-IND development in 2027 with potential targets expanding beyond oncology.
1. AI-Driven Pipeline Discovery
GT Biopharma has implemented AI-guided sequence and structural analyses to design de novo tumor-targeting engagers and multi-domain proteins with optimized binding, stability and developability profiles, replacing trial-and-error methods.
2. Anticipated Pre-IND Candidates in 2027
The company anticipates multiple new development candidates moving into pre-IND development in 2027, expanding its pipeline targets and indications beyond oncology to diversify therapeutic opportunities.
3. Efficiency Gains and Cost Reduction
AI-based structural modeling is also being used for construct refinement prior to resource-intensive in vitro and in vivo studies, resulting in shorter development timelines and lower projected R&D costs per candidate.
